ClinicalTrials.gg
TerminatedNCT03496623PERFECTUpdated Nov 24, 2023Results posted

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of Inhaled treprostinil solution and Placebo solution in Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease, sponsored by United Therapeutics. Terminated at 76 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-24.

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor's decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.

Enrollment
9th of 37
188 · median 32
Started
2018
with 2 others
Phase 3
15 of 38
1 open now
Registered
29th of 38
by date
Lead sponsor
25 of 38
United Therapeutics

Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 9th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2018, is one of 15 in phase 3, and was the 29th registered.

Hypertension, Pulmonary

1,091 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing treprostinil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

The primary objective of this study is to demonstrate the efficacy of inhaled treprostinil compared to placebo in improving exercise ability as measured by change from baseline in 6-Minute Walk Distance (6MWD) following 12 weeks of active treatment in participants with PH-COPD.

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled, 34-week, cross-over study, with a Treatment Period of approximately 26 weeks under the Original Crossover Design or, if applicable, a 21-week parallel study, with a Treatment Period of approximately 14 weeks under the Contingent Parallel Design.

03

Conditions studied

  • Pulmonary Hypertension
  • Chronic Obstructive Pulmonary Disease

Keywords

  • Pulmonary Hypertension
  • COPD
  • Inhaled Treprostinil
  • 6-Minute Walk Test
  • Tyvaso
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants who meet the following criteria may be included in the study:

  1. Participant voluntarily gives to participate in the study.
  2. Males and females 18 years of age and above at the time of informed consent.

    1. Women of (defined as less than 1 year and not surgically sterile) must agree to practice abstinence or use 2 highly effective methods of (defined as a method of birth control that results in a low failure rate, [\<1% per year], such as approved hormonal contraceptives, barrier methods [such as condom or diaphragm] used with a spermicide, or an intrauterine device) for the duration of study treatment and for 48 hours after discontinuing study drug. Participants must have a negative pregnancy test at the Screening Visit 1 (urine [prior to the first dose of study medication] and serum) and Baseline Visit (Study Week 1) (urine).
    2. Males with a partner of childbearing potential must agree to use a barrier method (condom) with a spermicide for the duration of treatment and for at least 48 hours after discontinuing study drug.
  3. Diagnosis of PH- (World Heath Organization [WHO] Group 3).
  4. Clinical diagnosis of COPD will be made using the Global Initiative for Chronic

    Obstructive Lung Disease (GOLD) diagnostic criteria (GOLD Criteria 2020) and spirometry with the following documented parameters measured during Screening Visit 1 (prior to start of low-dose inhaled treprostinil):

    1. (FEV1) \<80% predicted
    2. FEV1/Forced vital capacity (FVC) \<70
  5. The participant has a resting saturation peripheral capillary oxygenation (SpO2) greater than or equal to 90%, with or without supplemental oxygen, but not to exceed 10 liters (L)/min oxygen supplementation by any mode of delivery during Screening Visit 1.
  6. During Screening Visit 1 prior to start of low-dose inhaled treprostinil, a 6MWD greater than or equal to 100 meters.
  7. Have a right heart catheterization (RHC) performed during Screening Visit 1. (A previous RHC obtained within 12 months prior to the start of Screening Visit 1 is acceptable for determining eligibility, even if done without oxygen or vasodilator challenge, and a repeat RHC is not required.) The following parameters must be documented for eligibility:

    1. Pulmonary vascular resistance (PVR) greater than or equal to 4 Wood units
    2. A pulmonary artery wedge pressure (PAWP) or left ventricular end-diastolic pressure (LVEDP) of less than or equal to 15 millimeters of mercury (mmHg)
    3. A Pulmonary artery pressure mean (PAPm) of greater than or equal to 30 mmHg
  8. Participants must be on a stable and optimized dose of chronic COPD medications for greater than or equal to 30 days prior to start of Screening Visit 1 and remain on the same dose throughout the Screening Period.
  9. In the opinion of the Investigator, the participant can communicate effectively with study personnel and is considered reliable, willing, and likely to be cooperative with protocol requirements, including attending all study visits.

Exclusion criteria

Exclusion Criteria:

The following will exclude participants from the study:

  1. The participant has a diagnosis of either pulmonary arterial hypertension (PAH) or pulmonary hypertension (PH) due to reasons other than . This would include, but is not limited to, chronic thromboembolic PH or acute/recent deep vein thrombosis or pulmonary embolism, untreated or inadequately treated obstructive sleep apnea, connective tissue disease (including but not limited to systemic sclerosis/scleroderma or systemic lupus erythematosus), sarcoidosis, -1 infection, and other conditions under WHO Group 1, 2, 4, and 5 classifications.
  2. Based on chest computed tomography (CT) imaging during Screening Visit 1, the participant has a confirmed diagnosis of WHO Group 3 PH, other than COPD, such as idiopathic pulmonary fibrosis, combined pulmonary fibrosis and emphysema, diffuse parenchymal lung disease or interstitial lung disease. A previous chest CT scan performed within the 6 months prior to the start of Screening Visit 1 is also acceptable, and a repeat assessment is not required.

    A redacted CT scan report (from Screening Visit 1 or dated within prior 6 months) should be provided to the Medical Monitor with the Pre-Baseline Review Form to confirm eligibility.

  3. The participant has received any Food and Drug Administration (FDA)-approved medication for the treatment of PAH (that is, prostacyclin, prostacyclin receptor agonist, endothelin receptor antagonist [ERA], phosphodiesterase type 5 inhibitor [PDE5-I], or soluble guanylate cyclase [sGC] stimulator) at Screening Visit 1 and thereafter, except if received for acute vasoreactivity testing.
  4. The participant has a previous diagnosis of homozygous alpha-1 antitrypsin deficiency.
  5. The participant has any prior intolerance to inhaled prostanoid therapy.
  6. Inability to tolerate low-dose (3 breaths, 18 mcg) study drug and/or inability to follow dosing regimen during the Screening Period (pre-randomization).
  7. Unwilling or unable to use Sponsor-provided devices (actigraph, spirometer, or smart device).
  8. The participant has evidence of left-sided heart disease (including but not limited to \<40%, left ventricular hypertrophy,) or clinically significant cardiologic conditions, such as congestive heart failure, coronary artery disease, or valvular heart disease. Note: Participants with abnormal left ventricular function attributable to the effects of right ventricular overload will not be excluded, but a discussion with and approval by the Sponsor Medical Monitor is needed.
  9. Any exacerbation of COPD (including hospitalization or outpatient therapy) or active pulmonary or upper respiratory infection 60 days prior to start of Screening Visit 1 through the Baseline Visit. This is defined as worsening of respiratory symptoms that required treatment with and/or antibiotics.
  10. Initiation of pulmonary rehabilitation within 12 weeks prior to start of Screening Visit 1 or, in the opinion of the Investigator, pulmonary rehabilitation is likely to be needed during the study Treatment Period.
  11. The participant has any form of congenital heart disease (repaired or unrepaired; other than a patent foramen ovale).
  12. The participant has any musculoskeletal disorder (severe arthritis of the lower limbs which limits ambulation, recent hip or knee joint replacement, artificial leg) or any other condition that would likely be the primary limitation to ambulation.
  13. Use of any other drug or device within 30 days prior to the start of Screening Visit 1.
  14. Any other clinically significant illness or abnormal laboratory value(s) measured during the Screening Period that, in the opinion of the Investigator, might adversely affect the interpretation of the study data or safety of the participant.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    Inhaled Treprostinil

    Inhaled treprostinil delivered via an ultrasonic nebulizer with a target dosing regimen of 12 breaths (72 micrograms \[mcg\]) 4 times daily (QID)

    Drug: Inhaled treprostinil solution

  • Placebo comparator
    Placebo

    Placebo delivered via an ultrasonic nebulizer for QID administration

    Drug: Placebo solution

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in 6-Minute Walk Distance (6MWD)

    6 MWD was calculated at peak exposure (10 to 60 minutes after dosing). 6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course for 6 minutes (timed) and the distance walked (in meters) was recorded. Statistical analyses were not performed due to lack of appropriate sample size.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline to Week 12 in Moderate to Vigorous Physical Activity (MVPA)

    MVPA was defined as the number of minutes spent in moderate to vigorous physical activity as measured via a wrist-worn medical grade physical activity monitor. The screening data were used to establish a baseline level of physical activity.

    Time frame: Baseline, Week 12

  2. Change From Baseline to Week 12 in Overall Activity

    Overall activity was defined as the number of minutes spent in overall activity (non-sedentary activity) as measured via a wrist-worn medical grade physical activity monitor. The screening data will be used to establish a baseline level of physical activity.

    Time frame: Baseline, Week 12

  3. Change From Baseline to Week 12 in Borg Dyspnea Score

    The Borg Dyspnea Score was a 11-point scale rating the maximum level of dyspnea experienced during the 6-minute walking test (6MWT). Scores range from 0 (no dyspnea at all) to 10 (very, very severe dyspnea), with lower scores indicating a less exertion (a better outcome). The Borg Dyspnea Score was to be evaluated immediately after the 6MWT.

    Time frame: Baseline, Week 12

  4. Change From Baseline to Week 12 in 6MWD/Borg Dyspnea Composite Score

    6MWD was calculated at peak exposure (10 to 60 minutes after dosing). 6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course for 6 minutes (timed) and the distance walked (in meters) was recorded. The Borg Dyspnea Score was an 11-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (no dyspnea at all) to 10 (very, very severe dyspnea), with lower scores indicating less exertion (a better outcome). The Borg Dyspnea Score was to be evaluated immediately after the 6MWT. The average 6WMWD data and the average Borg Dyspnea Composite Score data were summed and reported as the composite score.

    Time frame: Baseline, Week 12

  5. Change From Baseline to Week 12 in Quality of Life (QOL) Measured by St. George's Respiratory Questionnaire (SGRQ)

    The SGRQ is a designed to measure how breathing impacts overall health, daily life, and perceived well-being in participants with obstructive airways disease. Scores range from 0 to 100, with lower scores indicating a better QoL.

    Time frame: Baseline, Week 12

  6. Change From Baseline to Week 12 in QOL Measured by the University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ)

    The UCSD SOBQ is a self-administered rating of dyspnea associated with activities of daily living. The questionnaire uses a 6-point scale where 0 = "not at all" and 5 = "maximal or unable to do because of breathlessness". Lower scores indicate a better QoL.

    Time frame: Baseline, Week 12

  7. Change From Baseline to Week 12 in Plasma Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Levels

    The NT-proBNP concentration is a biomarker associated with changes in right heart morphology and function. Improvement is defined as a decrease in the NT-proBNP plasma concentration.

    Time frame: Baseline, Week 12

  8. Change From Baseline to Week 12 in Patient Global Assessment (PGA)

    The PGA is used to rate participant fatigue and shortness of breath. Participants will use the Sponsor-provided smart device for at-home capture of PGA data. The PGA used a 5-point response scale of: "never," "rarely," "sometimes," "often," or "always" with higher scores indicating a worse symptom rating.

    Time frame: Baseline, Week 12

07

Results

Posted Nov 24, 2023
Limitations and caveats
Per sponsor decision, the study was terminated early. Data were not collected for the secondary outcome measures due to study termination and lack of appropriate sample size.

Participant flow

188 participants were enrolled; 80 of the 188 enrolled participants were screen failures prior to the Run-In Period. Per prespecified analysis, data were not collected for the participants who were screen failures.

Run-In Period (2 Weeks)
Participant flow — Run-In Period (2 Weeks)
MilestoneRun-InOriginal Crossover Design - Treprostinil, Then PlaceboOriginal Crossover Design - Placebo, Then TreprostinilContingent Parallel Design - TreprostinilContingent Parallel Design - Placebo
Started1080000
Received at least 1 dose of study drug1080000
Completed760000
Not completed320000
Withdrew: Death10000
Withdrew: Discontinued prior to randomization310000
Period 1 (12 Weeks)
Participant flow — Period 1 (12 Weeks)
MilestoneRun-InOriginal Crossover Design - Treprostinil, Then PlaceboOriginal Crossover Design - Placebo, Then TreprostinilContingent Parallel Design - TreprostinilContingent Parallel Design - Placebo
Started0323266
Received at least 1 dose of study drug0323266
Completed0262954
Not completed06312
Withdrew: Death03000
Withdrew: Study terminated by sponsor00012
Withdrew: Withdrawal by subject03300
Period 2 (12 Weeks)
Participant flow — Period 2 (12 Weeks)
MilestoneRun-InOriginal Crossover Design - Treprostinil, Then PlaceboOriginal Crossover Design - Placebo, Then TreprostinilContingent Parallel Design - TreprostinilContingent Parallel Design - Placebo
Started0262900
Received at least 1 dose of study drug0202800
Completed0192100
Not completed07800
Withdrew: Covid-19 pandemic impact04500
Withdrew: Lost to follow-up00100
Withdrew: Study terminated by sponsor00100
Withdrew: Withdrawal by subject03100

Outcome measures

PrimaryChange From Baseline to Week 12 in 6-Minute Walk Distance (6MWD)

6 MWD was calculated at peak exposure (10 to 60 minutes after dosing). 6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course for 6 minutes (timed) and the distance walked (in meters) was recorded. Statistical analyses were not performed due to lack of appropriate sample size.

Time frame:
Baseline, Week 12
Reported as:
Mean · meters
Change From Baseline to Week 12 in 6-Minute Walk Distance (6MWD)
metersOriginal Crossover Design - TreprostinilOriginal Crossover Design - PlaceboContingent Parallel Design - TreprostinilContingent Parallel Design - Placebo
Baseline225.07 ± 77.41220.47 ± 77.64231.50 ± 60.77283.00 ± 67.78
Change at Week 12-4.47 ± 39.01-5.14 ± 50.7120.33 ± 116.9918.5 ± 42.49
SecondaryChange From Baseline to Week 12 in Moderate to Vigorous Physical Activity (MVPA)

MVPA was defined as the number of minutes spent in moderate to vigorous physical activity as measured via a wrist-worn medical grade physical activity monitor. The screening data were used to establish a baseline level of physical activity.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 12 in Overall Activity

Overall activity was defined as the number of minutes spent in overall activity (non-sedentary activity) as measured via a wrist-worn medical grade physical activity monitor. The screening data will be used to establish a baseline level of physical activity.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 12 in Borg Dyspnea Score

The Borg Dyspnea Score was a 11-point scale rating the maximum level of dyspnea experienced during the 6-minute walking test (6MWT). Scores range from 0 (no dyspnea at all) to 10 (very, very severe dyspnea), with lower scores indicating a less exertion (a better outcome). The Borg Dyspnea Score was to be evaluated immediately after the 6MWT.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 12 in 6MWD/Borg Dyspnea Composite Score

6MWD was calculated at peak exposure (10 to 60 minutes after dosing). 6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course for 6 minutes (timed) and the distance walked (in meters) was recorded. The Borg Dyspnea Score was an 11-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (no dyspnea at all) to 10 (very, very severe dyspnea), with lower scores indicating less exertion (a better outcome). The Borg Dyspnea Score was to be evaluated immediately after the 6MWT. The average 6WMWD data and the average Borg Dyspnea Composite Score data were summed and reported as the composite score.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 12 in Quality of Life (QOL) Measured by St. George's Respiratory Questionnaire (SGRQ)

The SGRQ is a designed to measure how breathing impacts overall health, daily life, and perceived well-being in participants with obstructive airways disease. Scores range from 0 to 100, with lower scores indicating a better QoL.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 12 in QOL Measured by the University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ)

The UCSD SOBQ is a self-administered rating of dyspnea associated with activities of daily living. The questionnaire uses a 6-point scale where 0 = "not at all" and 5 = "maximal or unable to do because of breathlessness". Lower scores indicate a better QoL.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 12 in Plasma Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Levels

The NT-proBNP concentration is a biomarker associated with changes in right heart morphology and function. Improvement is defined as a decrease in the NT-proBNP plasma concentration.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 12 in Patient Global Assessment (PGA)

The PGA is used to rate participant fatigue and shortness of breath. Participants will use the Sponsor-provided smart device for at-home capture of PGA data. The PGA used a 5-point response scale of: "never," "rarely," "sometimes," "often," or "always" with higher scores indicating a worse symptom rating.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

Adverse events

Collected over Up to 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-In1/108 (0.9%)9/108 (8.3%)50/108 (46.3%)
Treprostinil5/66 (7.6%)17/66 (25.8%)36/66 (54.5%)
Placebo0/58 (0%)6/58 (10.3%)25/58 (43.1%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventRun-InTreprostinilPlacebo
Acute respiratory failureRespiratory, thoracic and mediastinal disorders3/1080/663/58
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/1083/661/58
Acute myocardial infarctionCardiac disorders0/1080/662/58
AnaemiaBlood and lymphatic system disorders0/1080/661/58
Atrial fibrillationCardiac disorders0/1080/661/58
Cardiac failure acuteCardiac disorders1/1080/661/58
Cardiogenic shockCardiac disorders0/1080/661/58
Pulseless electrical activityCardiac disorders0/1080/661/58
Ischaemic hepatitisHepatobiliary disorders0/1080/661/58
PneumoniaInfections and infestations0/1081/661/58
Most frequent other events
Showing 10 of 13
Most frequent other events
EventRun-InTreprostinilPlacebo
DyspnoeaRespiratory, thoracic and mediastinal disorders19/10819/669/58
CoughRespiratory, thoracic and mediastinal disorders16/10811/663/58
FatigueGeneral disorders2/1087/662/58
HeadacheNervous system disorders9/1087/664/58
Oropharyngeal painRespiratory, thoracic and mediastinal disorders9/1083/662/58
Chest discomfortGeneral disorders3/1085/660/58
Upper respiratory tract infectionInfections and infestations1/1082/664/58
DizzinessNervous system disorders2/1084/662/58
Productive coughRespiratory, thoracic and mediastinal disorders5/1084/662/58
ArthralgiaMusculoskeletal and connective tissue disorders0/1082/663/58

Baseline characteristics

Full Analysis Set included all participants who were randomized and received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Original Crossover DesignContingent Parallel Design - TreprostinilContingent Parallel Design - PlaceboTotal
Mean67.6 ± 7.8370.3 ± 6.7173.3 ± 2.1669.7 ± 8.01
Sex: Female, Male
Sex: Female, Male(Participants)Original Crossover DesignContingent Parallel Design - TreprostinilContingent Parallel Design - PlaceboTotal
Female310233
Male336443
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Original Crossover DesignContingent Parallel Design - TreprostinilContingent Parallel Design - PlaceboTotal
Hispanic or Latino2024
Not Hispanic or Latino626472
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Original Crossover DesignContingent Parallel Design - TreprostinilContingent Parallel Design - PlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American151218
White475456
More than one race2002
Unknown or Not Reported0000
08

Study locations

76 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Banner University Medical Center
    Phoenix, Arizona 85006, United States
  • University of Arizona Clinical and Translational Science (CATS) Research Center
    Tucson, Arizona 85724, United States
  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • West Los Angeles VA Healthcare Center
    Los Angeles, California 90073, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • Santa Barbara Pulmonary Associates
    Santa Barbara, California 93102, United States
  • University of Colorado Health Sciences Center
    Aurora, Colorado 80045, United States
  • South Denver Cardiology
    Littleton, Colorado 80120, United States
  • Hartford Hospital
    Hartford, Connecticut 06106, United States
  • MedStar Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • St. Francis Medical Institute
    Clearwater, Florida 33765, United States
  • University of Florida Clinical Research Center
    Gainesville, Florida 32610, United States
  • St. Vincent's Lung, Sleep, and Critical Care Specialists
    Jacksonville, Florida 32204, United States
  • Mayo Clinic - Jacksonville
    Jacksonville, Florida 32224, United States
  • Pulmonary Disease Specialists
    Kissimmee, Florida 34741, United States
  • University of Miami Hospital
    Miami, Florida 33136, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Pulmonary & Critical Care of Atlanta
    Atlanta, Georgia 30342, United States
  • Georgia Clinical Research
    Austell, Georgia 30106, United States
  • University of Illinois Medical Center
    Chicago, Illinois 60612, United States
  • Advocate Aurora Health Care
    Elmhurst, Illinois 60126, United States
  • Advocate Condell Medical Center
    Libertyville, Illinois 60048, United States
  • Advocate Heart Institute & Pulmonology
    Normal, Illinois 06176, United States
  • Edward Heart Hospital
    Oakbrook Terrace, Illinois 60181, United States
  • Indiana University Healh North Hospital
    Indianapolis, Indiana 46202, United States
  • St. Vincent Medical Group, Inc.
    Indianapolis, Indiana 46260, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
  • Kentuckiana Pulmonary Associates
    Louisville, Kentucky 40202, United States
  • University of Louisville Research Foundation
    Louisville, Kentucky 40202, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Detroit Medical Center Lung Institute
    Detroit, Michigan 48201, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Spectrum Health
    Grand Rapids, Michigan 49546, United States
  • Beaumont Health
    Troy, Michigan 48085, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • The University of New Mexico
    Albuquerque, New Mexico 87106, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • The Mount Sinai Hospital
    New York, New York 10029, United States
  • University of Rochester Medical Center
    Rochester, New York 14623, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27517, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • The Carl and Edyth Lindner Research Center at the Christ Hospital
    Cincinnati, Ohio 45219, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Clinical Research Associates of Central PA, LLC
    DuBois, Pennsylvania 15801, United States
  • Temple Lung Center
    Philadelphia, Pennsylvania 19140, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh Medical Center - Montefiore
    Pittsburgh, Pennsylvania 15213, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Statcare Pulmonary Consultants
    Knoxville, Tennessee 37909, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Texas Tech
    El Paso, Texas 79905, United States
  • Clear Lake Specialties/Tranquility Research
    Webster, Texas 77598, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
  • Pulmonary Associates of Richmond, Inc.
    Richmond, Virginia 23230, United States
  • Carilion Clinic
    Roanoke, Virginia 24014, United States
  • University of Wisconsin School of Medicine and Public Health
    Madison, Wisconsin 53792, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Hospital Britanico de Buenos Aires
    Buenos Aires, 1280AEB, Argentina
  • El Cruce Hospital
    Buenos Aires, Argentina
  • Fundacion Favaloro
    Ciudad Autonoma Buenos Aires, C1093AAS, Argentina
  • Hospital Italiano de Buenos Aires
    Ciudad Autonoma Buenos Aires, C1093AAS, Argentina
  • Hospital Italiano de Cordoba
    Cordoba, Argentina
  • Centro Medico 21 de Diciembre
    Santa Fe, Argentina
  • Lady Davis Carmel Medical Centre
    Haifa, 34362, Israel
  • Hadassah-Hebrew University Hospital
    Jerusalem, 9112001, Israel
  • Rabin Medical Center
    Petah Tiva, 49100, Israel
  • The Chaim Sheba Medical Center
    Tel Hashomer, 52621, Israel
  • CardioPulmonary Research Center
    Guaynabo, 00968, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Oct 2022, 53 months.

Results were first posted in Nov 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2018
First posted
Apr 12, 2018
StartActual
May 8, 2018
Primary completionActual
Oct 13, 2022
CompletionActual
Oct 13, 2022
Results first posted
Nov 24, 2023
Last update
Nov 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03496623
Responsible party
Sponsor
First posted
Apr 12, 2018
Start date
May 8, 2018
Primary completion
Oct 13, 2022
Completion
Oct 13, 2022
Results posted
Nov 24, 2023
Last update
Nov 24, 2023

Study contacts

Medical Director
study director · United Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion